NCT05464823

Brief Summary

To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
111

participants targeted

Target at P50-P75 for not_applicable lymphoma

Timeline
12mo left

Started Jul 2022

Typical duration for not_applicable lymphoma

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Jul 2022May 2027

Study Start

First participant enrolled

July 7, 2022

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

July 12, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 19, 2022

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 12, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 12, 2027

Last Updated

March 4, 2026

Status Verified

March 1, 2026

Enrollment Period

4.8 years

First QC Date

July 12, 2022

Last Update Submit

March 2, 2026

Conditions

Lymphoma

Outcome Measures

Primary Outcomes (1)

  • Percentage of participants who have genomic test results available in <=7 days

    through study completion an average of 1 year

Study Arms (1)

Molecular Testing

OTHER

Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Other: Molecular Functional Portrait

Interventions

Molecular Functional PortraitOTHER

Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test

Molecular Testing

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male/female patients who are at least 18 years of age on the day of informed consent signing.
  • Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
  • Provision of written informed consent for the study.

You may not qualify if:

  • \. None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Jason Westin, MD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2022

First Posted

July 19, 2022

Study Start

July 7, 2022

Primary Completion (Estimated)

May 12, 2027

Study Completion (Estimated)

May 12, 2027

Last Updated

March 4, 2026

Record last verified: 2026-03

Locations

US(1)